首页 | 本学科首页   官方微博 | 高级检索  
     

Rho激酶抑制剂对动脉瘤性蛛网膜下腔出血后迟发性脑血管痉挛的疗效研究
引用本文:封硕,李爱民,刘希光,李宁. Rho激酶抑制剂对动脉瘤性蛛网膜下腔出血后迟发性脑血管痉挛的疗效研究[J]. 临床神经外科杂志, 2011, 8(3): 122-123. DOI: 10.3969/j.issn.1672-7770.2011.03.004
作者姓名:封硕  李爱民  刘希光  李宁
作者单位:1. 徐州医学院附属连云港医院神经外科,222002
2. 徐州医学院附属连云港第一人民医院神经外科
摘    要:目的 探讨Rho 激酶抑制剂对动脉瘤性蛛网膜下腔出血(aSAH)后迟发性脑血管痉挛(DCVS)的治疗效果.方法 按照是否应用Rho 激酶抑制剂对35 例自发性性蛛网膜下腔出血后发生迟发性脑血管痉挛的患者资料和治疗效果进行回顾性分析.结果 Rho 激酶抑制剂对迟发性脑血管痉挛临床症状改善率81.25%,与常规治疗组47.37%相比,具有统计学差异(P<0.05);治疗后,Rho 激酶抑制组脑血流速度低于对照组(P<0.05).结论 Rho 激酶抑制剂能明显缓解aSAH 后迟发性脑血管痉挛的临床症状,为神经外科防治迟发性脑血管痉挛提供了临床依据.

关 键 词:蛛网膜下腔出血  迟发性脑血管痉挛  Rho激酶抑制剂

Study on Rho-kinase inhibitor therapy for delayed cerebral vasospasm following aneurysmal subarachnoid hemorrhage
Affiliation:FENG Shuo,LI AI-min,LIU Xi-guang( Lianyungang Hospital Affiliated to Xuzhou Medical College, Lianyungang 222002, China)
Abstract:Objective To explore the therapeutic effects of Rho-kinase inhibitor in treatment of delayed cerebral vasospasm (DCVS)following aneurysmal subarachnoid hemorrhage (aSAH). Methods The clinical data of 35 patients with DCVS following aSAH by Rho-kinase inhibitor were analyzed retrospectively. Results The response rate in control group and Rho-kinase inhibitor therapy group were 47.37 % and 81.25 % which with the significant difference ( P 〈 0.05 ). The flow velocity of middle cerebral artery (MCA) was significantly lower in Rho-kinase inhibitor therapy group than in control group ( P 〈 0.05 ). Conclusion Rho-kinase inhibitor has a good effect on the therapeutic of DCVS following aSAH for the control of DCVS.
Keywords:subarachnoid hemorrhage  delayed cerebral vasospasm  Rho-kinase inhibitor
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号